---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059812"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:25:00.485237+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corbus Q3 net loss $10.1M; pipeline progress with CRB-701, CRB-601, CRB-913

## Summary
- Net loss of $10.1M ($2.27 per diluted share) vs $8.8M ($2.11) in Q3 2022.
- Cash, equivalents, and investments of $28.7M as of Sept 30, 2023.
- CRB-701 Phase 1 dose escalation ongoing; early clinical data expected Q1 2024 alongside U.S./EU trial start.
- IND submission for CRB-601 on track for Q4 2023; pre-clinical data presented at SITC.
- CRB-913 pre-clinical study published in Obesity; shows no lean muscle loss when combined with incretins.

## SEC filing metadata
- accession: 0000950170-23-059812
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/0000950170-23-059812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/crbp-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059812
- JSON: https://secwatch.observer/filing/0000950170-23-059812.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059812.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported financial results for the third quarter of 2023.
  - Period: the third quarter of 2023
  - Result: reported results
  source text: today provided a corporate update and reported financial results for the third quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/0000950170-23-059812-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.